Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Natl Cancer Inst
Main Authors: Brastianos, Priscilla K., Shankar, Ganesh M., Gill, Corey M., Taylor-Weiner, Amaro, Nayyar, Naema, Panka, David J., Sullivan, Ryan J., Frederick, Dennie T., Abedalthagafi, Malak, Jones, Pamela S., Dunn, Ian F., Nahed, Brian V., Romero, Javier M., Louis, David N., Getz, Gad, Cahill, Daniel P., Santagata, Sandro, Curry, William T., Barker, Fred G.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2015
Teme:
Brief Communication
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4862417/
https://ncbi.nlm.nih.gov/pubmed/26498373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djv310
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki